Serum drug level monitoring in affective disorders

Krska, Janet; Corner, D A

doi:10.1111/j.1365-2710.1992.tb01318.x

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TDM is strongly recommended for most tricyclic antidepressants. It reduces the risk of toxicity [168,669,827,934,959,961,964,1304]. For many tricyclic antidepressants, a concentration -clinical effectiveness relationship (concentration-effect curve) has been shown.…”

Section: Level 3: Usefulmentioning

confidence: 99%

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Bergemann²,

et al. 2017

View full text Add to dashboard Cite

Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug-drug interactions are typical indications for TDM. However, the potential benefits of TDM to optimize pharmacotherapy can only be obtained if the method is adequately integrated in the clinical treatment process. To supply treating physicians and laboratories with valid information on TDM, the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued their first guidelines for TDM in psychiatry in 2004. After an update in 2011, it was time for the next update. Following the new guidelines holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.

show abstract

Section: Level 3: Usefulmentioning

confidence: 99%

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Bergemann²,

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Some studies attribute these differences to patients' sex, age, body weight, and physiology [7]. Other studies suggest that these variations are related to the plasma concentrations of carbamazepine and its dose [8], with the explanation that monitoring plasma carbamazepine concentrations may play a useful role in the management of patients with bipolar disorder. Moreover, it may be possible that the metabolic polymorphism of carbamazepine elimination, attributed to genetic and/or environmental origins, modifies carbamazepine plasma concentration and elimination and thus its psychotherapeutic effects.…”

Section: Original Articlementioning

confidence: 99%

Relationships between pharmacokinetic parameters of carbamazepine and therapeutic response in patients with bipolar disease

Chbili

Bannour

Khlifi

et al. 2014

Annales De Biologie Clinique

View full text Add to dashboard Cite

This study aimed to assess the relationship between plasma levels of carbamazepine and its active metabolite 10,11-epoxide-carbamazepine, and the therapeutic response in patients with bipolar disease. Thirteen patients were kept on a fixed individual dose of carbamazepine for 19 weeks under psychiatric care. Steady-state plasma concentrations of carbamazepine and its metabolite 10,11-epoxide-carbamazepine were measured at weeks 4, 12, and 20 by HPLC essay. Simultaneously, the psychopathologic state was assessed using the Brief Psychiatric rating scale (BPRS). Upon correlational analysis, mean BPRS scores did not correlate with the plasma levels of carbamazepine, whereas both mean plasma levels of 10, 11-epoxide-carbamazepine concentrations and 10,11-epoxide-carbamazepine to plasma carbamazepine ratio were closely correlated with mean values of BPRS scores (r = 0.80, p =10 -4 , r = -0.89, p =10 -3 respectively). Optimum therapeutic response was observed among patients who had a plasma metabolite level of 1.4 g/mL and a plasma carbamazepine concentrations of 7 g/mL simultaneously. These results suggest that both plasma carbamazepine and 10,11-epoxide-carbamazepine levels must be fixed to achieve optimum therapeutic response. In order to reach these conditions, inhibitor drugs (such as valproic acid) or inductor drugs (such as phenobarbital) of epoxyde-hydrolase might be coadministered with the carbamazepine in order to adapt the plasma level of 10,11-epoxide-carbamazepine.

show abstract

Relations entre les concentrations plasmatiques de la carbamazépine et 10,11-époxyde-carbamazépine, la dose carbamazépine, et la réponse clinique chez les patients bipolaires tunisiens

Chbili

Amor

Salah

et al. 2016

Annales Médico-psychologiques, revue psychiatrique

View full text Add to dashboard Cite

Serum drug level monitoring in affective disorders

Cited by 4 publications

References 12 publications

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Relationships between pharmacokinetic parameters of carbamazepine and therapeutic response in patients with bipolar disease

Relations entre les concentrations plasmatiques de la carbamazépine et 10,11-époxyde-carbamazépine, la dose carbamazépine, et la réponse clinique chez les patients bipolaires tunisiens

Contact Info

Product

Resources

About